Hope for insulin mimetic oral antidiabetic drugs

European Journal of Endocrinology

Volumn 141, Issue 6, 1999, Pages 561-562

  Shalev, Anath ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; NORASTERRIQUINONE B1; ORAL ANTIDIABETIC AGENT; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG RECEPTOR BINDING; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0033382911     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410561     Document Type: Short Survey

References (9)

1. Zhang B, Salituro G, Szalkowski D, Li Z, Zhang Y, Royo I et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999 284 974-977.
2. Saudek CD. Novel forms of insulin delivery. Endocrinology and Metabolism Clinics of North America 1997 26 599-610.
3. Leslie CA. New insulin replacement technologies: overcoming barriers to tight glycemic control. Cleveland Clinic Journal of Medicine 1999 66 293-302.
4. Kipnes M, Otulana B, Clauson P, Fischer J, Farr SJ, Hatorp Vet al. A comparison of the pharmacodynamic effects of inhaled insulin versus subcutanous insulin in type 1 diabetic patients. Diabetes 1999 48 (Suppl 1) A95.
5. Weiss SR, Berger S, Cheng SL, Kourides I, Landschulz WH, Gelfand RA, for the Phase II Inhaled Insulin Study Group. Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: a multicenter phase II trial. Diabetes 1999 48 (Suppl 1) A12.
6. Meyerhoff C, Stern W, Beer B, Ramaswamy M & Allaudeen H. Orally active insulin: proof of concept study in normal volunteers. Diabetes 1999 48 (Suppl 1) A105.
7. Medicherla S, Dey D, Neogi P & Nag B. CLX-0900 markedly increases glucose and cholesterol homeostasis in animal models of diabetes. Diabetes 1999 48 (Suppl 1) A118-A119.
8. Nag B. Medicherla S & Dey D. Orally active peptides for the treatment of type 1 and late-stage type 2 diabetes. Diabetes 1999 48 (Suppl 1) A355.
9. Lee J. Miyazaki M & Shoclson SE. Insulin receptor activation with transmembrane domain ligands. Diabetes 1999 48 (Suppl 1) A328-A329.